Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer modelsDouglas D. Fang(Pfizer (United States)), Yifan Zhai(Ascepion Pharmaceuticals (China))BMC CancerJuly 11, 202210.1186/s12885-022-09799-4Cited by 31SaveCiteExport RISWatch citationsRelated PapersActivating <i>JAK1</i> mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma|Oncotarget|2015|49Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation|PLoS ONE|2013|44Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors|Cell & Bioscience|2019|17